셀루메티닙

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Danger

• 유해·위험 문구

  H317：알레르기성 피부 반응을 일으킬 수 있음

  H318：눈에 심한 손상을 일으킴

  H373：장기간 또는 반복 노출되면 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킬 수 있음

• 예방조치문구

  P262：눈, 피부, 의복에 묻지 않도록 하시오.

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P312：불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.

셀루메티닙 화학적 특성, 용도, 생산

• 개요

  Selumetinib (AZD6244; ARRY-142886) is an oral MEK inhibitor. In a randomized trial, NSCLC patients with wild-type KRAS were randomized to erlotinib alone or combination therapy with selumetinib, while mutant KRAS patients were randomized to selumetinib alone or combination therapy. The primary end points were PFS for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Results were not impressive, with no PFS difference in the KRAS wild-type arm (2.4 vs. 2.1?months) and no ORR difference in the KRASmutated subgroup (0% vs. 10%). A planned trial of selumetinib in combination with the anti-PD-L1 antibody durvalumab has since been suspended (NCT03004105).

• 정의

  ChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv ly. It is a MEK1 and MEK2 inhibitor.

• 상표명

  Koselugo

• 일반 설명

  Class: dual threonine/tyrosine kinase; Treatment: children with NF1; Other name: AZD-6244, ARRY-142886; Oral bioavailability = 62%; Elimination half-life = 6.2 h; Protein binding = 97.7%

• Dosage

  Selumetinib is characterized by a moderate oral bioavailability (62%) and a relatively short half-life (6.2 h), and these properties contribute to twice-daily dosing regimen (25 mg dosage).

셀루메티닙 준비 용품 및 원자재

셀루메티닙 공급 업체

Global(326)Suppliers